PRF Technologies Ltd. (NASDAQ: PRFX)

PRF Technologies Ltd. is a specialty pharmaceutical company that was incorporated under the laws of the State of Israel in November 2007 under the name PainReform Ltd. The company changed its name to PRF Technologies Ltd. on January 6 2026 following shareholder approval. Its principal executive offices are located at 65 Yigal Alon St. Tel Aviv 6744316 Israel. The company’s proprietary extended release drug delivery system is designed to provide prolonged therapeutic effect after a single administration. PRF Technologies Ltd. focuses on reformulating generic drugs to create extended release product candidates that can be approved via the FDA’s 505 b 2 pathway. Its lead pharmaceutical programs are PRF 110 an extended release formulation of ropivacaine for post surgical pain relief and OcuRing™ K a sustained release ocular implant that delivers ketorolac following cataract surgery. In March 2025 PRF Technologies Ltd. acquired the AI driven solar analytics business DeepSolar which offers software solutions to monitor and optimize the performance of solar energy assets. The DeepSolar technology integrates with SCADA systems and provides real time analytics automated reporting and technical due diligence services.

PRF Technologies Ltd. generates revenue primarily from the potential future sale of its pharmaceutical product candidates after they receive regulatory approval. The company intends to commercialize PRF 110 and OcuRing™ K through direct sales to hospitals ambulatory surgery centers and ophthalmology clinics or through strategic partnerships with larger pharmaceutical firms. In addition PRF Technologies Ltd. earns revenue from its DeepSolar segment by offering subscription based access to its solar analytics platform and by providing professional services such as technical due diligence and performance monitoring. The DeepSolar business also derives income from pilot projects and early adoption agreements with solar energy producers. Although the company is still in the development stage it has begun to generate limited revenue from DeepSolar pilot programs.

The company operates through two reportable segments: Specialty Pharmaceuticals and DeepSolar AI Analytics.

• The Specialty Pharmaceuticals segment focuses on developing and commercializing extended release drug products based on the company’s proprietary drug delivery system. Its lead programs include PRF 110 an extended release formulation of ropivacaine for post surgical pain relief which completed a Phase 3 trial in bunionectomy patients and OcuRing™ K a sustained release ocular implant that delivers ketorolac following cataract surgery and is advancing toward a Phase 2 clinical trial.

• The DeepSolar segment provides an AI driven solar analytics software platform that monitors system performance identifies inefficiencies and optimizes energy yield. The technology offers features such as smart live monitoring performance analytics event management automatic verification report generation and management dashboards. DeepSolar also delivers professional services including technical due diligence under its Smart TDD offering which provides comprehensive asset assessments for solar power plants. The company has executed a pilot project with Econergy Renewable Energy Ltd. at a 92 megawatt photovoltaic plant in Romania and continues to expand its customer base among solar operators and residential home owners.

PRF Technologies Ltd. occupies a specialized niche in the pharmaceutical industry where it leverages a proprietary drug delivery platform to reformulate generic molecules for extended release indications. The company’s competitive advantages include its well characterized safety profile the use of GRAS excipients and the ability to avoid complex handling requirements associated with some existing extended release products. In the postoperative pain market PRF 110 competes with established products such as Exparel Zynrelef Marcaine and Naropin but differentiates itself through a lower cost of manufacture and a simpler administration technique. In the ophthalmic market OcuRing™ K addresses the shortcomings of traditional eye drop regimens by providing a drop less sustained release alternative that competes with devices from Optomed PanOptica Lenz Therapeutics and Rayner. In the solar analytics market DeepSolar distinguishes itself through its AI driven diagnostic capabilities its ROI focused task lists and its seamless integration with a wide range of SCADA systems competing against providers such as Power Factors Green Project Management and Meteocontrol.

The company serves hospitals ambulatory surgery centers and ophthalmology clinics for its pharmaceutical product candidates PRF 110 and OcuRing™ K. It also targets cataract surgeons and postoperative care units as potential end users of its extended release formulations. For its DeepSolar solar analytics business the customer base includes commercial solar farm operators residential home owners independent power producers infrastructure funds lenders and insurers. The company has named Econergy Renewable Energy Ltd. as an early adopter and pilot partner for its DeepSolar services in Romania. Additionally DeepSolar engages with solar asset owners seeking technical due diligence and performance monitoring solutions.